Mannkind (MNKD) Treasury Shares (2011 - 2026)

Mannkind (MNKD) reported Treasury Shares of $18.1 million for Q1 2026, up 9.63% on a QoQ basis from $16.5 million in Q4 2025.

Mannkind (MNKD) has 16 years of Treasury Shares data on file, last reported at $18.1 million in Q1 2026.

Quarterly Treasury Shares changed N/A year-over-year to $18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.1 million (changed N/A YoY) and the FY2025 annual result came in at $16.5 million, up 16.68% from the prior year.
Treasury Shares improved to $18.1 million in Q1 2026 per MNKD's latest filing, from $16.5 million in the prior quarter.
Across five years, Treasury Shares topped out at $18.1 million in Q1 2026 and bottomed at $11.8 million in Q4 2022.
The 5-year median for Treasury Shares is $14.1 million (2024), against an average of $14.6 million.
The widest annual swing landed in 2022, when Treasury Shares gained 24.12%; it then rose 4.44% in 2023.
Tracing MNKD's Treasury Shares over 5 years: stood at $11.8 million in 2022, then gained by 4.44% to $12.4 million in 2023, then advanced by 14.28% to $14.1 million in 2024, then rose by 16.68% to $16.5 million in 2025, then grew by 9.63% to $18.1 million in 2026.
Per Business Quant, the three latest MNKD Treasury Shares figures stand at $18.1 million (Q1 2026), $16.5 million (Q4 2025), and $14.1 million (Q4 2024).

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn	-
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-	265,401.92
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn	700,000.00
7	Evaxion A	62.56 Bn	62.54 Bn	-	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn	34.70 Mn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn	-
10	Mannkind	1.09 Bn	956.66 Mn	82.66 Mn	18.07 Mn

Download Data 🔒